| http://www.w3.org/ns/prov#value | - Whilst this has proven true for oncogenes such as bcr-abl and kit [38], current evidence suggests that mutations in EGFR may not predict response to EGFR inhibitors in lung cancer [39, 40], and B-Raf mutations in melanoma do not currently appear to predict response to sorafenib [41], a compound which inhibits B-Raf activity.It should be noted that MCF10A cells, which are karyotypically normal and
|
